(Q36641509)

15 August 2017

1 reference

title

Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications (English)

1 reference

15 August 2017

1 reference

Robert M Prins

3

0 references

Linda Liau

1 reference

ORCID Public Data File 2021

author name string

Meng-Yin Yang

1

1 reference

15 August 2017

Paul M Zetler

2

1 reference

15 August 2017

Haumith Khan-Farooqi

4

1 reference

15 August 2017

Linda M Liau

5

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

1481-1494

1 reference

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Biodegradable polymer implants to treat brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Immunology and immunotherapy in neurosurgical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

All in the head: obstacles for immune rejection of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Activation of human macrophages by amyloid-beta is attenuated by astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect of glioma-derived factors on antigen presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Basic principles of immunological surveillance of the normal central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Intracerebral regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

A self-defence mechanism of astrocytes against Fas-mediated death involving interleukin-8 and CXCR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Paraneoplastic Syndromes Involving the Nervous System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Immunological update on multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

AIM-2: a novel tumor antigen is expressed and presented by human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Gene expression profiling identifies molecular subtypes of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Identification of molecular subtypes of glioblastoma by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Immunologic approaches to antigen discovery for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Gene expression profiling of gliomas strongly predicts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Cellular immunity and immunotherapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Robustness of gene expression profiling in glioma specimen samplings and derived cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Targeted toxin therapy for malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Interleukin-13 receptor as a unique target for anti-glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Adoptive immunotherapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Adoptive cellular immunotherapy for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Cytokine gene therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Live bacteria as the basis for immunotherapies against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Therapeutics targeting the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Current status of clinical trials for glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Human Alloreactive CTL Interactions with Gliomas and with Those Having Upregulated HLA Expression from Exogenous IFN-γ or IFN-γ Gene Modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1481

10.1586/14737175.6.10.1481

21 January 2018

Identifiers

DOI

1 reference

release_qycybcarjngfhmmanut5kpzbj4

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qycybcarjngfhmmanut5kpzbj4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference